Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy

Dalian University

Status and phase: Unknown; Phase 1

Conditions: Hepatocellular Carcinoma

Treatments: Drug: Placebo - Concentrate; Procedure: transcatheter arterial chemoembolization; Drug: CpG DNA

Study type: Interventional

Funder types: Other

Identifiers

NCT03235167

zsyy_zxsys2017-07

Details and patient eligibility

About

to observe the outcome of hepatocellular carcinoma patients under the combination treatment of transcatheter arterial chemoembolization (TACE) and CpG DNA

Enrollment: 100 estimated patients

Sex: All

Ages: 55 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• TNM (tumor node metastasis ) staging with non distant metastasis; no other tumors

Exclusion criteria

• having received previous treatment for liver cancer

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Factorial Assignment

Masking: Quadruple Blind

---

100 participants in 2 patient groups, including a placebo group

CpG DNA

Experimental group

Description:

CpG DNA concentrate

Treatment:

Drug: CpG DNA

Procedure: transcatheter arterial chemoembolization

placebo

Placebo Comparator group

Description:

placebo concentrate

Treatment:

Procedure: transcatheter arterial chemoembolization

Drug: Placebo - Concentrate